Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Peng

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Molecular Cancer Therapeutics|March 16, 2021
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor TherapyDavid M Briere, Shuai Li, Andrew Calinisan, et al.
Cancer Research|January 6, 2021
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLCJessica M Konen, B Leticia Rodriguez, Aparna Padhye, et al.
The Journal of Clinical Investigation|April 26, 2014
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonismYanan Yang, Young-Ho Ahn, Yulong Chen, et al.
Nature Communications|September 10, 2020
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8<sup>+</sup> T cell exhaustionDavid H Peng, Bertha Leticia Rodriguez, Lixia Diao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2015
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung CancerRenata Ferrarotto, Ruchitha Goonatilake, Suk Young Yoo, et al.
Frontiers in Immunology|July 14, 2023
Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistanceB Leticia Rodriguez, Limo Chen, Yanli Li, et al.
Molecular Cancer Research : MCR|November 11, 2020
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR InhibitorsKavya Ramkumar, C Allison Stewart, Kasey R Cargill, et al.
Nature Communications|November 14, 2019
ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancerRoxsan Manshouri, Etienne Coyaud, Samrat T Kundu, et al.
Science Translational Medicine|March 15, 2019
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanismDavid H Peng, Samrat T Kundu, Jared J Fradette, et al.
Journal of Cancer Research and Clinical Oncology|November 19, 2020
PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern CaliforniaGino K In, Poorva Vaidya, Alexandra Filkins, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Molecular Cancer Therapeutics|March 16, 2021
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor TherapyDavid M Briere, Shuai Li, Andrew Calinisan, et al.
Cancer Research|January 6, 2021
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLCJessica M Konen, B Leticia Rodriguez, Aparna Padhye, et al.
The Journal of Clinical Investigation|April 26, 2014
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonismYanan Yang, Young-Ho Ahn, Yulong Chen, et al.
Nature Communications|September 10, 2020
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8<sup>+</sup> T cell exhaustionDavid H Peng, Bertha Leticia Rodriguez, Lixia Diao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2015
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung CancerRenata Ferrarotto, Ruchitha Goonatilake, Suk Young Yoo, et al.
Frontiers in Immunology|July 14, 2023
Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistanceB Leticia Rodriguez, Limo Chen, Yanli Li, et al.
Molecular Cancer Research : MCR|November 11, 2020
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR InhibitorsKavya Ramkumar, C Allison Stewart, Kasey R Cargill, et al.
Nature Communications|November 14, 2019
ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancerRoxsan Manshouri, Etienne Coyaud, Samrat T Kundu, et al.
Science Translational Medicine|March 15, 2019
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanismDavid H Peng, Samrat T Kundu, Jared J Fradette, et al.
Journal of Cancer Research and Clinical Oncology|November 19, 2020
PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern CaliforniaGino K In, Poorva Vaidya, Alexandra Filkins, et al.
Pageof 6